01 — At a Glance
The Suppository King Nobody Talks About
- 52-Week High / Low₹244 / ₹105
- Q3 FY26 Revenue₹218 Cr
- Q3 FY26 PAT₹25 Cr
- TTM EPS₹10.33
- Annualised EPS (Q3 Avg × 4)₹8.80
- Book Value / Share₹107
- Price to Book1.86x
- Debt to Equity0.05x
- Interest Coverage15.6x
- Export %94%
Reality Check: Q3 PAT of ₹25 crore looks modest until you realize this company made that profit selling tiny pharmaceutical products in Africa. The stock is up 58% in one year, 39% in three years. Nobody in your office talked about it. Nobody on CNBC mentioned it. And that, my friends, is how quiet compounders are made.
02 — Introduction
What Do They Sell? Trust Us, You Need It More Than You Know
Bliss GVS Pharma makes suppositories, pessaries, capsules, tablets, and syrups. If you’ve never heard these words except in a health textbook, congratulations — your digestive system is either blessed or just privately independent.
Founded in 1984, this ₹2,100 crore market cap company exports pharmaceutical formulations to over 60 countries, with 94% of sales going overseas — mostly to Africa. In Africa, Bliss is not just a company; it’s practically a household name. While Indians argue about stock multiples, Bliss is busy treating malaria, fungal infections, and inflammation across the sub-Saharan region like a pharmaceutical missionary with better margins.
The company has 7 manufacturing facilities (5 in Maharashtra, 2 in Nigeria), CRISIL BBB+/Stable rating (the same rating given to well-managed small NBFCs), and ₹172 crore sitting in its bank account as of March 2025. It also contract-manufactures for Sun Pharma and Mankind — meaning it makes pills for bigger companies too. Think of it as the humble supplier everyone depends on but nobody credits.
The Africa Thing: 65% of revenue comes from African countries. This is either a huge risk or a genius move depending on whether you believe Africa’s health spending will grow faster than its population. Bliss is betting heavily that it will. Meanwhile, it’s also diversifying into CIS countries, Russia, and Europe. Baby steps out of the African comfort zone.
03 — Business Model: Making Tiny Pills, Big Profits
The Unsexy Pharma Business That Actually Makes Money
Members get full access to every article.
